Clinical Trial Search

Primary: Quality of Life in Alzheimer's Disease (QOL-AD)--Participants With Dementia (PWD) — 35.42; 38.10; 35.56; 36.12 score on a scale

Primary: Rate of Change of Hippocampal Volume Slope — -70.2418748; -88.4738591; -94.0768115; -46.9484805 mm^3/year — p=0.095

Primary: Change in Quality of Life-Alzheimer's Disease Score — 12.32; 15.88 score on a scale

Primary: Ratio of Cerebral N Acetyl-Aspartate (NAA) / Cerebral Creatine — 1.49; 1.42 Ratio

Primary: Participant Interest in PET Biomarker Disclosure — 73 Participants

Primary: Word List Memory Total - ADAS-cog — 14.35; 14.7; 15.1; 14.67 Words recalled

Primary: California Verbal Learning Test II — 6.9; 6.2; 6.46; 5.10 units on a scale — p=0.048

Primary: Incidence of Hospital Transfers (Patients) — 0.99; 1.12 events per person day at risk — p=0.522

Primary: Change in Baseline Burden and Stress of Caregivers Over 3 Months — -52.0; -31.9 percentage change

Primary: Symptoms of Agitation as Measured by the Pittsburgh Agitation Scale — 7.14; 5.55; 5.69; 4.97 score on a scale — p=.015

Primary: Change From Baseline in the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog 14) Score at Week 12 — -1.26; -1.28; -1.68; -1.01 score on a scale — p=0.9819

Primary: Time to Dispensing of Inappropriate Medication Prescription — 76.7; 77.9; 77.5 Percentage of Cumulative Incidence — p=0.76

Primary: Number of Participants That Completed Patient Quality of Life Survey — 4; 3; 3; 3 Participants

Primary: Change From Baseline to Week 12 in the Cohen-Mansfield Agitation Inventory (CMAI) Composite Score — 73.7; 68.8; 71.3; -16.2 score on a scale — p=0.789

Primary: Change From Baseline in Neuropsychiatric Inventory (NPI) Psychosis Subscale Score at Week 10 in Acute Phase — 12.12; 12.29; -5.52; -6.55 Units on a scale — p=0.802

Primary: Donepezil Maximum Tolerated Dose (MTD) — 0; 0; 0; 0 Participants

Primary: Stage 1 and Stage 2: Change From Baseline in the Cohen-Mansfield Agitation Inventory (CMAI) Composite Score to Week 6 and Week 12 — 73.9; 72.3; 71.7; -10.7 units on a…

Primary: Success Rate of Adherence — 2; 6; 7 Participants — p=0.12

Primary: Change in Connectivity Measure of the TGd Parcellations. — 0.5 abnormal connections

Primary: Rate of Change on the ADAS-Cog 11. — 7.98; 8.27 ADAS points per year

Primary: 12-Month Cumulative Incidence of ADRD Diagnoses — 213; 134; 355 Number of new ADRD cases — p=0.006

Primary: Functional Connectivity Scores Between Pairs of Large Scale Brain Networks. — 0.164; 0.374; 0.344; 0.340 connectivity score

Primary: Change From Baseline in Neuropsychological Test Battery in Total Z-score After 12-week Treatment. — 0.35; 0.20; 0.26; 0.32 z-score — p=0.3236

Primary: Dispensing of Psychotropic Medications — 161; 315 Participants — p=0.492

Primary: Percentage of Recruited Subjects Able to Comply With the Protocol — 12; 13; 3; 14 Participants

Primary: Acute Safety — 2 participants

Primary: Change From Baseline in Clinician Interview-Based Assessment of Change Plus Caregiver Input (CIBIC-Plus) Global Score (New York Univeristy Version) — 2.3; 5.22 units on…

Primary: Regionally Averaged Cerebral Glucose Uptake Changes Measured by FDG PET Uptake With Voxel-based Method — 81.70; 80.40; 84.60; 81.33 Bq/Bq (no unit) — p=0.14

Primary: Evaluations of Behavioral Disorders — 68; 66; 36; 69 Scores on a scale — p=1

Primary: Caregiver Self-efficacy at 12 Months Among Caregivers With Unmet Health Related Social Needs — 3.5; 3.5 score on a scale